Alzheimer’s Disease: Eight-Market Drug Forecast and Market Analysis

Alzheimer’s Disease: Eight-Market Drug Forecast and Market Analysis

Summary

This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033.

GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France.By the end of the forecast period in 2033, GlobalData projects AD sales to rise to $19.3 billion in the 8MM, at a compound annual growth rate (CAGR) of 23.4%.

Scope

• Overview of Alzheimer’s Disease, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Alzheimer’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global Alzheimer’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer’s Disease therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer’s Disease therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.